Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 1, 2003, Pages 32-43

  Simonsson, Ulrika S H ^a   Jansson, Britt ^b   Hai, Trinh Ngoc ^b   Huong, Dinh Xuan ^b   Tybring, Gunnel ^b   Ashton, Michael ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; BIOLOGICAL MARKER; CARBOXYTOLBUTAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; HYDROXYTOLBUTAMIDE; ISOENZYME; MEPHENYTOIN; NORMEPHENYTOIN; OMEPRAZOLE; TOLBUTAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME ACTIVITY; HUMAN; HYPOGLYCEMIA; MALE; NAUSEA; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT; TIME SERIES ANALYSIS; URINARY EXCRETION; VERTIGO;

ADULT; AREA UNDER CURVE; ARTEMISININS; ARYL HYDROCARBON HYDROXYLASES; CONFIDENCE INTERVALS; ENZYME INDUCTION; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; PHENOTYPE; SESQUITERPENES;

EID: 0038434501     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00092-4     Document Type: Article

References (38)

1. Ashton M, Hai TN, Sy ND, Huong DX, Van Huong N, Nieu NT, et al. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos 1998;26:25-7.
2. Svensson USH, Ashton M, Trinh NH, Bertilsson L, Dinh XH, Nguyen VH, et al. Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 1998;64:160-7.
3. Mihara K, Svensson USH, Tybring G, Hai TN, Bertilsson L, Ashton M. Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19. Fundam Clin Pharmacol 1999;13:671-5.
4. Ashton M, Nguyen DS, Nguyen VH, Gordi T, Trinh NH, Dinh XH, et al. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 1998;63:482-93.
5. Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M. Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob Agents Chemother 2002;46:1026-31.
6. Svensson USH, Alin H, Karlsson MO, Bergqvist Y, Ashton M. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol 2002;58:339-51.
7. Gupta S, Svensson USH, Ashton M. In vitro evidence for auto-induction of artemisinin metabolism in the rat. Eur J Drug Metab Pharmacokinet 2001;26:173-8.
8. Svensson USH, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 1999;48:528-35.
9. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, et al. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 1999;9:295-306.
10. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30:795-804.
11. Donato MT, Viitala P, Rodriguez-Antona C, Lindfors A, Castell JV, Raunio H, et al. CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab Dispos 2000;28:1321-6.
12. Svensson USH, Sandstrom R, Carlborg O, Lennernas H, Ashton M. High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement. Drug Metab Dispos 1999;27:227-32.
13. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993;306:240-5.
14. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
15. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984;26:753-9.
16. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-80.
17. Kupfer A, Roberts RK, Schenker S, Branch RA. Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther 1981;218:193-9.
18. Kupfer A, Desmond PV, Schenker S, Branch RA. Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J Pharmacol Exp Ther 1982;221:590-7.
19. Wedlund PJ, Aslanian WS, Jacqz E, McAllister CB, Branch RA, Wilkinson GR. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther 1985;234:662-9.
20. Heyn H, White RB, Stevens JC. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 1996;24:948-54.
21. Ko JW, Desta Z, Flockhart DA. Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab Dispos 1998;26:775-8.
22. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990;252:442-7.
23. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 1989;28:4993-9.
24. Srivastava PK, Yun CH, Beaune PH, Ged C, Guengerich FP. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 1991;40:69-79.
25. Yasumori T, Yamazoe Y, Kato R. Cytochrome P-450 human-2 (P-450IIC9) in mephenytoin hydroxylation polymorphism in human livers: differences in substrate and stereoselectivities among microheterogeneous P-450IIC species expressed in yeasts. J Biochem (Tokyo) 1991;109:711-7.
26. Veronese ME, McManus ME, Laupattarakasem P, Miners JO, Birkett DJ. Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450. Drug Metab Dispos 1990;18:356-61.
27. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991;175:1112-8.
28. Nelson E, O'Reilly I. Kinetics of carboxytolbutamide excretion following tolbutamide and carboxytolbutamide administration. J Pharmacol Exp Ther 1961;132:103-9.
29. Thomas R, Ikeda G. The metabolic fate of tolbutamide in man and in the rat. J Med Chem 1966;9:507-10.
30. Jackson PR, Tucker GT, Lennard MS, Woods HF. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 1986;22:541-50.
31. Tucker GT, Rostami-Hodjegan A, Jackson PR. Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Xenobiotica 1998;28:1255-73.
32. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990;47:403-11.
33. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-63.
34. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6:547-51.
35. Gordi T, Nielsen E, Yu Z, Westerlund D, Ashton M. Direct analysis of artemisinin in plasma and saliva using coupled-column high-performance liquid chromatography with a restricted-access material pre-column. J Chromatogr B Biomed Sci Appl 2000;742:155-62.
36. Jansson B, Simonsson USH, Ashton M. Simultaneous enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4′-hydroxymephenytoin in human plasma by HPLC. J Chromatogr B Biomed Sci Appl. In press 2003.
37. Christensen M, Tybring G, Mihara K, Yasui-Furokori N, Carrillo JA, Ramos SI, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002;71:141-52.
38. Houston JB. Drug metabolite kinetics. Pharmacol Ther 1981;15:521-52.